1. Home
  2. SBGI vs CDNA Comparison

SBGI vs CDNA Comparison

Compare SBGI & CDNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Sinclair Inc.

SBGI

Sinclair Inc.

HOLD

Current Price

$15.31

Market Cap

1.0B

Sector

Industrials

ML Signal

HOLD

Logo CareDx Inc.

CDNA

CareDx Inc.

HOLD

Current Price

$19.29

Market Cap

1.0B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SBGI
CDNA
Founded
1986
1998
Country
United States
United States
Employees
N/A
N/A
Industry
Broadcasting
Medical Specialities
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.0B
1.0B
IPO Year
2023
2007

Fundamental Metrics

Financial Performance
Metric
SBGI
CDNA
Price
$15.31
$19.29
Analyst Decision
Buy
Buy
Analyst Count
5
7
Target Price
$21.80
$27.33
AVG Volume (30 Days)
399.5K
655.1K
Earning Date
05-26-2026
05-13-2026
Dividend Yield
6.53%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$3,169,000,000.00
$48,324,000.00
Revenue This Year
$10.60
$15.37
Revenue Next Year
N/A
$11.23
P/E Ratio
N/A
N/A
Revenue Growth
N/A
18.93
52 Week Low
$11.89
$10.96
52 Week High
$17.88
$21.49

Technical Indicators

Market Signals
Indicator
SBGI
CDNA
Relative Strength Index (RSI) 53.26 48.61
Support Level $14.43 $18.30
Resistance Level $15.62 $20.94
Average True Range (ATR) 0.76 0.93
MACD 0.12 -0.06
Stochastic Oscillator 50.09 65.12

Price Performance

Historical Comparison
SBGI
CDNA

About SBGI Sinclair Inc.

Sinclair Inc. is the owner-operator of the second largest portfolio of television stations in the United States, with 185 full power stations in 86 markets, covering 40% of US households. Of the firm's roughly 600 channels, 150 are affiliated with the four national broadcasters—Fox, ABC, CBS, and NBC—with over 80 other channels aligned with The CW (Nexstar) and MyNetworkTV (Fox). Sinclair owns the Tennis Channel and stakes in Marquee Sports Network and YES Network, providing their premium sports content to pay-TV distributors.

About CDNA CareDx Inc.

CareDx Inc operates as a precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers. It offers testing services, products, and digital solutions along with the pre- and post-transplant patient journey and is a provider of genomics-based information for transplant patients. The Company's commercially available testing services consist of AlloSure Kidney, AlloMap Heart, AlloSure Heart, a dd-cfDNA solution for heart transplant patients, and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. Geographically the company generates the majority of its revenue from the United States. The company generates the majority of revenue from the Testing services.

Share on Social Networks: